May 7, 2008 - GE Healthcare signed a nonexclusive agreement with Merck and Co. to provide spin signal technology (SST) for imaging of the lungs to help to advance respiratory treatment development, as part of GE Healthcare’s strategy to accelerate the development of new therapeutics.
GE Healthcare’s drug development strategy includes giving pharmaceutical companies access to novel molecular imaging agents to assess the impact of potential drugs in animal models and, when appropriate, human subjects.